Julie D Sutton

Learn More
We present an in-depth study of rheumatoid arthritis (RA) in a Chippewa band. Of the 227 band members, 168 (74%) were evaluated. The unusually high prevalence of RA was confirmed in 7.1% of those studied or, minimally, 5.3% with a 100% completion rate without additional cases found. Seropositivity in those with clinically definite RA was 92% relative to(More)
The long-term efficacy and safety of piroxicam 20 mg once daily in the treatment of osteoarthritis was evaluated in 30 patients--eight for three to five years, seven for six years, and 15 for more than seven years--for a total mean duration of six years. More than 93 percent (28/30) reported feeling well at the last visit, while 12 said they were either(More)
BACKGROUND Epidemiologic studies using half-mouth designs for assessment of periodontal disease prevalence have reported that environmental tobacco smoke (ETS) exposure of non-smokers is associated with a two- to three-fold increase in the odds of developing periodontitis. In response to the possibility of under-reporting of periodontitis, the Centers for(More)
PURPOSE The association of second hand smoke or environmental tobacco smoke (ETS) and periodontitis in non-smokers has not been confirmed using a biomarker of ETS exposure. To estimate periodontitis prevalence in non-smokers with detectable serum cotinine, and to investigate racial/ethnic and socioeconomic variation in ETS exposure in a representative(More)
This prospective, double blind study was undertaken to test the efficacy of intravenous "minipulse" (100 mg) methylprednisolone (MP) therapy versus standard pulse (1000 mg) MP therapy in rheumatoid arthritis (RA). Thirty-six patients with RA synovitis flares were randomized to receive either 100 or 1000 mg MP IV QD x 3 doses. These 2 universally comparable(More)
One hundred six ambulatory outpatients with systemic lupus erythematosus (SLE) seen during 1985 completed the Stanford Health Assessment Questionnaire (HAQ) and the Psychosocial Adjustment to Illness Scale (PAIS). Mean HAQ disability, pain and global assessment scores were 0.66, 0.81 and 29.4, respectively, indicating a mild amount of impairment.(More)
In a study of the long-term safety and efficacy of piroxicam (20 mg daily) in the treatment of osteoarthritis, 30 female patients with a mean duration of more than seven years of treatment were evaluated. Despite having had poor or no response with other drug therapies, in the majority of cases in which piroxicam was used half of the patients (15 of 30)(More)
This six-month double-blind, parallel-design study compared the efficacy and safety of piroxicam 20 mg and 40 mg with that of 12 tablets of aspirin in 29 patients with osteoarthritis and demonstrated that both piroxicam doses were superior to aspirin in the treatment of osteoarthritis with respect to physicians' opinion of improvement and ease of movement.(More)